Xeris Biopharma Holdings, Inc. - Common Stock (XERS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
XERS on Nasdaq
Shares outstanding
165,974,436
Price per share
$7.85
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
96,902,264
Total reported value
$788,823,196
% of total 13F portfolios
0%
Share change
+5,843,427
Value change
+$58,408,316
Number of holders
229
Price from insider filings
$7.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 6.7% $87,815,414 11,186,677 The Vanguard Group 31 Dec 2025

As of 30 Sep 2025, 229 institutional investors reported holding 96,902,264 shares of Xeris Biopharma Holdings, Inc. - Common Stock (XERS). This represents 58% of the company’s total 165,974,436 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.2% 11,927,699 +3.4% 0% $97,091,470
VANGUARD GROUP INC 5.9% 9,827,917 +0.11% 0% $79,999,244
D. E. Shaw & Co., Inc. 3.5% 5,839,886 +52% 0.04% $47,536,672
GEODE CAPITAL MANAGEMENT, LLC 2.5% 4,140,174 +13% 0% $33,707,992
STATE STREET CORP 2.3% 3,738,329 -1.2% 0% $30,429,998
Qube Research & Technologies Ltd 2% 3,274,834 +6% 0.04% $26,657,149
MORGAN STANLEY 1.9% 3,219,701 -12% 0% $26,208,367
Nuveen, LLC 1.7% 2,827,874 +8.7% 0.01% $23,018,895
Driehaus Capital Management LLC 1.6% 2,619,129 +26% 0.15% $21,319,710
Rosalind Advisors, Inc. 1.1% 1,795,766 -17% 5.3% $14,617,535
GOLDMAN SACHS GROUP INC 1.1% 1,795,455 -21% 0% $14,615,004
Parkman Healthcare Partners LLC 1.1% 1,791,674 -15% 1.6% $14,584,226
UBS Group AG 1.1% 1,782,734 +682% 0% $14,511,455
Connor, Clark & Lunn Investment Management Ltd. 1% 1,698,757 +38% 0.04% $13,827,882
RENAISSANCE TECHNOLOGIES LLC 0.98% 1,622,840 -21% 0.02% $13,209,919
TWO SIGMA INVESTMENTS, LP 0.97% 1,614,579 +33% 0.02% $13,142,673
BANK OF AMERICA CORP /DE/ 0.96% 1,594,866 -4.1% 0% $12,982,208
DEUTSCHE BANK AG\ 0.94% 1,567,645 +113% 0% $12,760,630
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.87% 1,446,619 +155% 0% $11,775,479
PRUDENTIAL FINANCIAL INC 0.86% 1,434,204 -7.9% 0.01% $11,674,421
NORTHERN TRUST CORP 0.82% 1,363,129 +5.4% 0% $11,095,869
Legal & General Group Plc 0.82% 1,357,427 -25% 0% $11,049,455
KENNEDY CAPITAL MANAGEMENT LLC 0.73% 1,211,583 +48% 0.22% $9,862,286
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.62% 1,034,553 +4% 0.03% $8,421,261
Knott David M Jr 0.61% 1,015,000 -4.2% 3.5% $8,262,100

Institutional Holders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 13,754,651 $107,945,928 +$4,075,602 $7.85 60
2025 Q3 96,902,264 $788,823,196 +$58,408,316 $8.14 229
2025 Q2 90,495,534 $422,617,978 +$16,622,096 $4.67 200
2025 Q1 86,799,982 $476,523,606 +$123,713,876 $5.49 199
2024 Q4 65,548,446 $222,208,577 +$5,693,687 $3.39 161
2024 Q3 63,918,467 $182,169,401 +$11,712,690 $2.85 143
2024 Q2 60,623,914 $136,403,872 +$57,516 $2.25 132
2024 Q1 60,495,199 $133,691,334 +$1,259,202 $2.21 140
2023 Q4 59,921,867 $140,817,138 +$3,980,290 $2.35 118
2023 Q3 55,319,172 $102,889,496 -$2,383,422 $1.86 109
2023 Q2 55,920,487 $146,506,955 +$17,809,976 $2.62 101
2023 Q1 49,463,144 $80,622,599 -$5,927,964 $1.63 89
2022 Q4 53,916,182 $71,703,555 -$5,395,029 $1.33 93
2022 Q3 57,306,752 $89,403,802 -$3,332,109 $1.56 97
2022 Q2 59,291,260 $91,305,115 +$12,225,836 $1.54 95
2022 Q1 50,404,861 $129,034,768 +$23,839,809 $2.56 97
2021 Q4 40,971,724 $120,062,000 +$117,961,261 $2.93 85
2021 Q3 704,170 $1,725,000 +$1,725,000 $2.45 1